APOBEC3B Has Dual Roles During the Evolution of Non-Small Cell Lung Cancer Available to Purchase

Major Finding: APOBEC3B inhibits early tumor growth but confers resistance to EGFR-targeted therapy in lung cancer.

Concept: EGFR-targeted therapy induces APOBEC3B-associated mutations in genes that promote drug resistance.

Impact: Targeting APOBEC3B may improve responses to EGFR-targeted therapy in patients with lung cancer.